Clinical Trials Directory

Trials / Completed

CompletedNCT00045266

VEGF Trap in Treating Patients With Solid Tumors or Non-Hodgkin's Lymphoma

An Open-Label, Long Term, Safety, and Tolerability Study of VEGF Trap in Patients With Incurable, Relapsed or Refractory Solid Tumors or Lymphoma

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
—
Sponsor
Regeneron Pharmaceuticals · Industry
Sex
All
Age
25 Years – 120 Years
Healthy volunteers
Not accepted

Summary

RATIONALE: VEGF Trap may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the cancer. PURPOSE: Phase I trial to study the effectiveness of VEGF Trap in treating patients who have relapsed or refractory solid tumors or non-Hodgkin's lymphoma.

Detailed description

OBJECTIVES: * Determine the long-term safety and tolerability of VEGF Trap in patients with incurable relapsed or refractory solid tumors or non-Hodgkin's lymphoma with stable or responding disease after receiving treatment on protocol MSKCC-01131. * Determine the biological effect of this therapy on suppressing tumor growth or progression in these patients. * Determine the steady state concentration of VEGF Trap over time in these patients. * Determine whether patients develop antibodies to this therapy during extended exposure. OUTLINE: This is an extension study for patients who showed evidence of stable disease or complete or partial remission after completing treatment on protocol MSKCC-01131. Patients continue to receive VEGF Trap subcutaneously once weekly for up to an additional 6 months in the absence of unacceptable toxicity. Patients receive treatment at the same dose level as on protocol MSKCC-01131. Patients are followed at approximately 30 days. PROJECTED ACCRUAL: A maximum of 30 patients will be accrued for this study.

Conditions

Interventions

TypeNameDescription
BIOLOGICALziv-aflibercept

Timeline

Start date
2002-04-01
Primary completion
2007-02-01
First posted
2003-01-27
Last updated
2016-06-03

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00045266. Inclusion in this directory is not an endorsement.